Journey Medical Corporation announced full-year 2025 financial results, with total revenues of $61.9 million, up 10% from $56.1 million in 2024, driven by Emrosi launch generating $14.7 million in net revenues. Net loss narrowed to $11.4 million or $(0.47) per share from $14.7 million or $(0.72) per share, with gross margin improving to 66.2%.
Key takeaways
Total revenues $61.9 million for FY2025, up 10% from $56.1 million in FY2024
Emrosi generated $14.7 million net revenues after April 2025 launch, with 53,000 prescriptions filled
Gross margin 66.2% for FY2025 vs 62.8% in FY2024
SG&A expenses $44.4 million for FY2025 vs $40.2 million in FY2024
Net loss $11.4 million or $(0.47) per share basic and diluted for FY2025 vs $14.7 million or $(0.72) per share in FY2024
Cash and equivalents $24.1 million and working capital $29.4 million at December 31, 2025